Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4529643 | 0.80 | MCOLN3 (0.49) | MCOLN3L3MBTL1POLBKMT2AMMP2 | |
| SCHEMBL4539209 | 0.75 | POLB (0.46) | MCOLN3L3MBTL1POLBKMT2AMEN1 | |
| SCHEMBL13934758 | 0.75 | MCOLN3 (0.46) | MCOLN3L3MBTL1POLBKMT2AMMP2 | |
| SCHEMBL13934759 | 0.73 | MCOLN3 (0.44) | MCOLN3L3MBTL1POLBKMT2AMMP2 | |
| SCHEMBL13934760 | 0.72 | MMP2 (0.43) | MCOLN3L3MBTL1KMT2AMMP2ALDH1A1 | |
| SCHEMBL4538996 | 0.71 | POLB (0.50) | MCOLN3L3MBTL1POLBKMT2AMMP2 | |
| SCHEMBL4527439 | 0.69 | GAA (0.53) | MCOLN3L3MBTL1POLBKMT2AMMP2 | |
| SCHEMBL13934757 | 0.69 | GAA (0.53) | MCOLN3L3MBTL1POLBKMT2AMMP2 | |
| SCHEMBL10845796 | 0.69 | CYP2D6 (0.47) | MCOLN3L3MBTL1POLBKMT2AMEN1 | |
| SCHEMBL29835687 | 0.68 | KMT2A (0.31) | L3MBTL1POLBKMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | MCOLN3 2688/4885L3MBTL1 3907/4885POLB 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.